

Antimicrobial Susceptibility Testing Paradigms: Current Status and Future Directions

Robert J. Tibbetts

Department of Pathology, Henry Ford Health System, Detroit, MI 48202.

Corresponding Author

Robert J. Tibbetts, Ph.D. D(ABMM), F(CCM). Associate Director Microbiology, Assistant Director, Pathology Residency Program. Department of Pathology and Laboratory Medicine. Henry Ford Health System. 2799 West Grand Blvd. Detroit, MI 48202

(313) 916-9381 Office

(313) 916-8309 Fax

rtibbet1@hfhs.org

Index Terms: Antimicrobial susceptibility testing, antimicrobial resistance

Abbreviations: AST – Antimicrobial susceptibility testing, AUC – Area under the curve, BMD – Broth microdilution, CFU – Colony forming unit, CLSI – Clinical and laboratory Standards Institute, CSF – Cerebral spinal fluid, ECV – Epidemiologic cut-off value, EMA – European Medicines Agency, EUCAST – European Committee on Antimicrobial susceptibility testing, FDA – Food and Drug Administration, FDA-CDER – FDA-Center for Drug Evaluation and Research, I – Intermediate, LIS – Laboratory information system, MIC – Minimum Inhibitory Concentrations, NAAT – Nucleic acid amplification techniques, NS – Non-susceptible, NWT – Non-wildtype, PAE – Post antimicrobial effect, PCR – Polymerase Chain Reaction, PD – Pharmacodynamics, PK – Pharmacokinetics, R – Resistant, S – Susceptible, SDD – Susceptible Dose-Dependent, USCAST – National Antimicrobial Susceptibility Testing Committee for the United States, UTI – Urinary tract infection, WT – Wildtype,.

Learning Objectives:

1. Explain the importance of antimicrobial susceptibility testing in management of patient care.
2. Describe various methods of antimicrobial susceptibility testing and their limitations.
3. Describe the governance and development of minimum inhibitory concentration breakpoints and challenges associated with global standardization of antimicrobial susceptibility testing and interpretation.

Abstract

Antimicrobial susceptibility testing (AST) results are among the most important pieces of information a clinical microbiology lab can release and clinicians rely heavily on them to care for their patients. Due to the clinical importance of these results, it is imperative that testing is performed under optimal conditions with standardized approaches to quality control, interpretation and reporting. There are a variety of *in vitro* methods to determine bacterial antimicrobial susceptibilities as well as interpretive criteria and testing limitations that have been vetted through the Clinical and laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial susceptibility testing (EUCAST). The goal in Part I of this two part section is to review the general background, breakpoint development and Governance of AST testing and in Part II review the standardization of the various method of AST, their limitations and associated challenges and review the future of antimicrobial susceptibility testing using newer technologies.

Part I.

Introduction

Clinicians rely greatly on all patient results generated from the microbiology laboratory; however, it has been suggested that antimicrobial susceptibility testing (AST) results may be the single most important to aid in the treatment of their most critically ill patients.¹⁻³ Not only do AST results drive infection specific management, temporally collected data can be used to drive empiric antimicrobial therapy in the form of yearly antibiograms and can be used to monitor the development and spread of resistance mechanisms.^{2,4} The use of dilution-based AST to gauge antimicrobial activity has been around since the discovery of penicillin in 1929 and Alexander Fleming described a tube-based dilution method determining penicillin minimum inhibitory

concentrations (MICs) of fungal culture filtrates.⁵ In its infancy, the performance of AST varied significantly from lab to lab regarding the entire process, i.e. composition of media, inoculum size, incubation conditions, and antimicrobial purity.⁴ However, over the past 30 years, AST has undergone a significant degree of procedural standardization and oversight by various agencies, i.e. CLSI resulting in very robust, reproducible and interpretable results from lab to lab across the world. While there are a number of *in vitro* methods to determine the potential *in vivo* efficacy of a particular antimicrobial agent not all are the same and discrepancies have been reported.⁶ The general lack of new antimicrobial drug classes and the high level of resistance to newer classes is a major cause of concern and demands robust testing and interpretive criteria. Therefore, the goal of the following review is to outline these tests and their limitations, governance and development of interpretive criteria, current challenges and the future direction of AST.

Governance of Antimicrobial Susceptibility Breakpoint Development and Testing

Minimum Inhibitory Concentrations (MIC). In antimicrobial susceptibility testing, the MIC is a numeric value that indicates the lowest concentration of an antimicrobial agent that inhibits growth of a bacterium *in vitro*.¹ The range of MICs are fundamental in the formation of susceptibility testing methods; they allow for comparison against achievable human serum levels for determining susceptibility and therefore provide the foundation for categorizing the numeric MIC results of AST to predict clinical outcome.^{2,7} According to the CLSI, there are 6 breakpoint categories that provide clinicians the information to drive therapeutic decision making.² Traditionally, these were defined as: “susceptible,” (S) indicating that when using Food and Drug Administration (FDA) approved standard dosing the antimicrobial concentrations are typically achievable for clinical cure; “intermediate” (I) suggests that the bacteria have MICs

at or near the high end of achievable antimicrobial concentrations and response rates may be lower than susceptible isolates; and “resistant” (R) indicates that achievable antimicrobial concentrations are not likely to have a favorable clinical response.¹ It is important to note that most breakpoints are based on achievable levels of a particular antimicrobial in serum only; therefore, depending on where the infection is located, these breakpoints may not necessarily correlate with clinical resolution using the FDA approved standard dose and duration of treatment.⁸ More recently, two additional breakpoint designations have been developed “Susceptible Dose-Dependent” (SDD) (similar to, yet has replaced “intermediate” for two drugs, suggests that with altered dosing strategies, antimicrobial concentrations will be achievable for clinical cure) and “Non-susceptible” (NS) (used when only a susceptible designation has been made due to the absence or rarity of bacteria resistant to that antimicrobial).^{1,8} Most recently a sixth designation is the Epidemiologic cut-off value (ECV).⁹ ECV’s are based solely on the *in vitro* MIC distribution of a particular antimicrobial and bacterium, not on *in vivo* or clinical cure data; therefore, they are very different than true MIC breakpoints.^{1,9} The ECV is determined using either a computer algorithm or, oftentimes, simply based on the wildtype (WT) distribution of the drug/bug combination, and any MIC that is greater than this ECV is considered to be a non-wildtype phenotype as described below and in Figure 1.¹ The benefit of using an ECV is that the ECV value is often low, so they are more sensitive at detecting small changes in antimicrobial susceptibility and new/emerging mechanisms of resistance.¹⁰ Since the clinical relevance of ECVs have not been determined, it is very important to note that ECV and breakpoints are not interchangeable but rather are used primarily to monitor the emergence of non-wildtype (NWT) strains of a particular bacterium.^{1,10}

The conventional method to determine the MIC is by using serial two-fold dilutions of a particular antimicrobial agent using either an agar dilution or broth microdilution (BMD) technique.⁷ This dilution was initially chosen for the ease of making the dilution series; however, the choice turned out to be a serendipitous, in part, because in the absence of a resistant determinant, any given bacterial species will have an MIC range to any given drug in a statistically normal distribution.⁷ This distribution then allows investigative organizations to determine the WT vs NWT MICs used, in part, to determine the categorical breakpoints.^{7,8} In very early evaluations of BMD techniques it was determined that 90% to 95% of MIC results were within +/- 1 dilution from the median for most drug/bug combinations.¹¹

A downside to this doubling dilution is that any error in a doubling dilution result, e.g., between two different methods or within the normal “error rate,” will represent at least a 2-fold difference.⁴ To be exact, when the lab reports that an organism has an MIC of 2 ug/ml, what they really mean is that it has an MIC of between 1 to 4 ug/ml.¹² Further, if this happens to occur at an established breakpoint, it may result in a different categorical designation, which may have unintended clinical consequences.⁴ Two very important scenarios related to this allowable error rate, whether it is between two different methods of AST or multiple AST results from a single method are major errors and very major errors.^{9,13} The former is when the reference result is susceptible and the other result is resistant and the latter is when the reference result is resistant and the other is susceptible. For a more thorough review of these errors and the allowable rates for AST testing see the CLSI M52 and M23 documents.^{14,15} Additionally, in a large Phase 3 clinical trial consisting of ~1500 patients with a gram-negative infection treated with cefotaxime it was noted that 64% of those patients with a cefotaxime resistance bacteria and 93% with a susceptible bacteria showed a favorable clinical outcome.¹² These results have been

corroborated in additional studies^{16, 17} and based on this and several other studies Rex and Pfaller coined the phrase “the 60/90 rule”; that is, infections due to susceptible isolates respond favorably to treatment ~90% of the time and those with infections due to resistant isolates respond favorably ~60% of the time, although this rule generally does not apply to immunocompromised patients those with multiple comorbidities.¹⁸

Lastly, breakpoint utilization is described in the form of disc diffusion AST (see more below). Breakpoints for the determination of S, I, or R are based the “zone of inhibition” of growth in millimeters around a paper disc impregnated with a fixed concentration of antimicrobial agent.⁹ Once the actual MIC breakpoints have been established the zone diameter breakpoints can then be determined. The primary method to do this is to test the bacteria and antimicrobial agent using both the broth dilution and disc diffusion methods and creating a scatter plot of the results with zone diameter on the y-axis and MIC on the x-axis.^{7, 8} Visual inspection of the correlation of MIC versus the zone diameter have allowed for the determination of where the breakpoints should be in millimeters (Figure 2).^{7, 8} For a much more detailed review of both methods of breakpoint development please see Turnidge and Paterson.⁸

Governance. In the United States there are three organizations involved in AST development and breakpoint interpretation guidelines: The FDA Center for Drug Evaluation and Research (FDA-CDER) the CLSI, and the National Antimicrobial Susceptibility Testing Committee for the United States (USCAST).^{2, 10, 19} CLSI is an international, interdisciplinary, non-for-profit, standards-developing educational organization whose goal is to promote the development and use of consensus-developed testing and interpretive guidelines for use in the health care industry.¹ Similarly, USCAST describes itself as “part of a global network dedicated to fighting the rise of antibiotic resistance through scientific, educational, and policy-creating activities.”²⁰

In contrast, the FDA is a government agency within the Departments of Health and Human services whose primary function, in part, is in the regulatory oversight of *in vitro* medical devices, for example, AST methodology. In Europe, the European Committee on Antimicrobial susceptibility testing (EUCAST) and European Medicines Agency (EMA) function in the same capacity respectively with the primary difference in that EMA funds EUCAST while the FDA does not fund CLSI.¹⁰ While their goals are the same, to develop functional breakpoints, how they go about analyzing the results can vary, and as a consequence, the breakpoints do not always match among them.^{2, 10}

Breakpoint Development. The process of breakpoint development is complex and involves numerous sources of data for the initial setting and continued data collection once approved and implemented. There are 4 main processes: 1) MIC distribution and wildtype cutoffs; 2) Pharmacokinetic (PK)/Pharmacodynamic (PD) data from both animal models and human studies; 3) clinical and bacteriological outcome data from clinical studies, and 4) genotypic and phenotypic *in vitro* resistance markers (described in Part II. Methods of AST in the clinical lab and individual limitations).⁸ *In vitro* modeling, i.e. “Monte Carlo simulation,” is also used to predict breakpoints.²¹ Turnidge and Paterson produced an excellent review of Monte Carlo simulation.⁸

The first step in the breakpoint development process is to collect MIC distribution data by testing thousands of individual bacterial/antimicrobial combinations using either BMD or agar-dilution methods.⁸ These data are arranged into histograms where the obvious WT/NWT cutoffs can be observed, forming the basis of the susceptible breakpoint (Figure. 1).⁸ If there is a single normal distribution it would suggest only a susceptible population exists, aka the wildtype

phenotype;²¹ however, a bimodal normal distribution would suggest that the bacterial population includes resistant isolates, aka the non-wildtype phenotype.^{8, 21}

The next step is an analysis of PK/PD data. PK is defined as the activity of the drug over time in the patient at the site of infection including absorption, distribution, and elimination, while PD is the effect of the drug on the infection and disease including pharmacological and toxicological.^{10, 22} Taken together, PK/PD is the study of the relationship between the activity of the drug and bactericidal/bacteriostatic effects *in vitro* and therefore by extension, clinical outcomes.⁸ The 4 indices incorporated by a drug's PK/PD and the MIC used to determine the killing effect of a particular antimicrobial are the length of time the free drug concentration (fT) remains above the MIC (fT>MIC), the ratio of peak free drug concentration (fCmax) to the MIC (fCmax:MIC), the ratio of the area under a 24-hour time curve of drug concentration (AUC) to the MIC (AUC:MIC), and the post antimicrobial effect (PAE) is the duration of bacterial regrowth following removal of the antimicrobial (12). Using these indices, antimicrobials can be classified into 3 types: 1) time-dependent action with no or short PAE, 2) time-dependent action and long lasting PAE, and 3) those with prominent concentration-dependent actions (Table 1).⁷ These indices allow for the determination of the maximum breakpoint (greater than this value would indicate resistant) that would allow the achievement of optimal antimicrobial efficacy using approved dosing schedules for the antimicrobial in question.⁷

It is important to note that PK/PD breakpoints are established using data from plasma/serum concentrations, which do not necessarily predict success in tissues or other body sites such as the CSF or synovial fluids.⁸ For example, an antimicrobial that tests susceptible *in vitro* on a bacterium from CSF may be a false susceptible if the antimicrobial does not cross the blood brain barrier.¹ Conversely, false resistance occurs very often on urinary isolates as some

drugs used for UTIs concentrate in much higher levels than can be achieved in serum. For a very detailed review of PK/PD including *in vitro* and *in vivo* animal modeling see Turnidge and Paterson.⁸

Once the MIC distribution and the WT/NWT breakpoint have been determined (plus Monte Carlo simulation, as applicable) and PK/PD parameters have been calculated, then tentative breakpoints can be determined and the study can proceed with clinical trials.⁹ Clinical trials are designed to test these tentative breakpoints by measuring the bacterial response rate, or successful eradication of the bacteria from the site of infection as well as the clinical response rate.⁹ In the US, the CLSI and the FDA are the primary stakeholders in breakpoint development and both use some or all of the aforementioned data sets to do so; however, the breakpoints can and often do differ.^{1,7,8} The clinical implications for these differences can be significant since FDA breakpoints are usually set when a new drug is introduced; some of the current FDA breakpoints were set decades ago prior to known resistance mechanisms and may be too high or too low resulting in inappropriate antimicrobial usage.¹⁰ In addition, pharmaceutical companies that are granted FDA approval for an antimicrobial can only use the FDA approved breakpoints in their product literature and as such, clinical labs must use these breakpoints despite the availability of more current or revised CLSI breakpoints.¹⁰

Taken together these discrepancies can and do create confusion for clinical microbiologists, AST device manufacturers, and clinicians.¹⁰ Therefore, the question of whether the CLSI and the FDA will band together to agree upon a single set of breakpoints has been posed numerous times.²¹ Despite the two organizations working together this has not happened until just recently. In December of 2016, the “21st Century Cures Act” was signed into law with the goal to “*ensure a more efficient process by which to update susceptibility test interpretive*

criteria to recognize antimicrobial resistance."¹⁹ The first action from this was that the FDA created an Antimicrobial Susceptibility Test Interpretive Criteria website that recognized and accepted breakpoints that were developed by the CLSI, which were typically published separately in the CLSI M100 and other CLSI documents, as well as their own breakpoints.¹⁹ While there are challenges ahead, this is a great first step in the unification of breakpoint development between the three organizations involved in the US to develop standardized MIC interpretation and categorization in order to predict clinical cure with both high sensitivity and specificity.

Part II.

Methods of AST in the clinical lab and individual limitations

Despite the potential differences in breakpoints, there is a global consensus on the way AST should be performed and the methods to perform them. Since the inception of AST by Fleming in 1929 using a tube-broth method, additional methods quickly arose out of necessity; ease of use, standardization, consistency and miniaturization were the driving factors. Antimicrobial activity can now be determined using a wide variety of different *in vitro* methods. These methods include disk diffusion, microbroth dilution, and Etests, which are manual or instrument-based automated methods.¹² With the exception of the disk diffusion method, all others provide actual MICs while disc diffusion results in categorical results (S, I, or R).

One of the biggest challenges in performing and resulting AST, regardless of the method used, is the clinical precision of the results and their predictive value for clinical cure.⁴ A number of studies have been performed that have sought to determine the major source(s) of AST variability, which determined that there are both biological and technical causes.⁴ Biological variability exists between different bacteria regarding growth phase/doubling times or

various nutritional or temperature requirements that may alter growth, while technical variability arises from non-standardized pre and post analytic handling of the bacteria and the media used during testing.⁴ To that end, both the CLSI and EUCAST have standardized these processes to ensure the least amount of variability including media types, incubation times and temperature, bacterial concentration, and assay performance, all of which are published in the CLSI M07-A11 document.³ In addition, both organizations provide recommendations on which bacteria/antimicrobial combinations to test, MIC categorical interpretation, and which bug/drug combinations to report in groups.¹

Test Methods. Phenotypic AST can be divided into two primary categories: broth dilution and agar based methods, with the latter being divided into agar diffusion and agar dilution.³ Broth dilution utilizes a pre-defined volume of a liquid growth medium, typically cation adjusted Mueller-Hinton (MH) broth, to which a known concentration of antimicrobial is added to the first tube. Serial two-fold dilutions are then made to subsequent tubes to the desired end-point dilution.³ A known concentration of bacteria (inoculum) is made and added to each tube. For this method, the starting inoculum is $1-5 \times 10^5$ CFU/ml. The tubes are incubated at 35 °C for 18-24 hours; the first tube showing no growth of bacteria (no turbidity in the broth) is the MIC. This process can occur in any starting volume; however, BMD is most common using 96-well disposable plates with 0.1 ml of broth.^{3,9} Furthermore, BMD is considered the “gold standard” of AST comparison in the clinical lab. The advantage of this method is that a single bacterium can be tested against 12 different antimicrobials with up to 8 two-fold dilutions thus generating MIC’s and the results are very reproducible.⁹ The disadvantage is the manual nature of preparing the plates and reporting results and in the case of commercially prepared plates, the cost and the relative inflexibility of antimicrobial choice and the length of time to get new panels

with newer drugs.⁹ This same method is what is typically used by commercially available automated systems, only the volumes are in the 10-20 ul range. The advantage of these systems is the automation, as results are determined and can be automatically uploaded into the laboratory information system (LIS) and patient medical record. The disadvantages are the same as those for broth dilution listed above.

For the agar based AST methods, the same MH broth is used but in a solid form from the addition of agar and the inoculum for agar based methods is diluted to $1-2 \times 10^8$ CFU/ml, aka a McFarland 0.5.³ Incubation, temperature, and time are the same as broth dilution. Two-fold antimicrobial dilutions are then made on individual agar plates so as an advantage of this method, bacterial inoculum are plated onto the agar using a “replica plater” apparatus, allowing for inoculation of up to 32 different bacteria per plate. In doing so, each bacterial species will be placed in the exact same location on all subsequent plates. Following incubation, the first plate where there is no colony growth is considered the MIC.³ Two major disadvantages to this method are 1) the potential for cross contamination of bacterial suspensions using a replica plater and 2) the manual nature of making agar plates correctly as the depth of the agar in the plate is crucial for result consistency; as such, this method is rarely, if ever used in the clinical lab.

Two other agar based methods utilize either paper discs or plastic strips impregnated with either a fixed amount of antimicrobial as in Kirby-Bauer disc diffusion or a gradient of antimicrobial agent as used in gradient strip diffusion.³ As the antimicrobial diffuses through the agar upon placement of the disc or strip, it creates either a round zone of antimicrobial with decreasing MICs moving away from the disc, or an elliptical zone of MICs with the highest at the top when using the gradient strips. Lack of growth around the disc or strip is called the “zone

of inhibition.” For the disc, the diameter of the zone determines if the bacteria is S, I, or R, for the strip, the lowest point where the growth ellipsis intersects the strip determines the MIC.^{3,9}

Lastly, genotypic AST occurs through the use of molecular based nucleic acid amplification techniques (NAAT) such as Polymerase Chain Reaction (PCR).²³ These types of assays often only look for one specific gene associated with one type of resistance, i.e. the *vanA* or *vanB* genes associated with vancomycin resistance in Enterococcus species or the *mecA* gene associated with methicillin resistance in Staphylococcus species. Despite only looking for a single gene, the presence of the gene may predict antimicrobial susceptibility to a wide range of antimicrobials; for example, *mecA* positive *S. aureus* is resistant to all beta-lactams not just methicillin.²³ As the need has grown, there are now a number of FDA approved commercially available “multiplex” systems that can detect multiple resistance genes simultaneously for example the Cepheid GenXpert[®] CarbaR test that detects KPC, NDM-1, IMP, VIM, and OXA-48 carbapenemases.²⁴ For a nice review of these systems and their targets please see Abbott and Fang.²³ The main advantages of molecular detection, in particular the commercially available systems, lie in the ease of use and turnaround time as most of these only take 1-2 hours as opposed to 18-24 hours incubation and they can detect multiple genes simultaneously. There are several disadvantages to these assays as well. First is the cost, since many of them are considerably more expensive than traditional AST in clinical labs. Second, outside of the few genes mentioned above, not all resistance genes can predict phenotypic resistance to multiple antimicrobials; for example, there are hundreds of beta-lactamases, point mutations confirming resistance to the quinolones, efflux pump mechanisms, and outer membrane porin mutations that our current genotypic methods of detection cannot easily detect.⁹ For a nice review on molecular detection of antimicrobial resistance determinants see Ledebor and Richard.²⁵

Challenges and Future Direction. Two of the biggest challenges to AST are 1) the creation and adoption of standardized breakpoints and 2) testing that is timely and comprehensive. As indicated previously, the roll out of the 21st Century Cures law has begun to tackle the issues of multiple organizations defining MIC breakpoints thereby standardizing how the MIC results are interpreted.¹⁹ In addition, the law will remove the constraints to the commercial AST developers allowing for a more rapid development of expanded test panels and the ability to change MICs with changing breakpoints.¹⁹ This then leads to the second challenge and the most likely direction AST will move to in the future: next generation sequencing and microbiome analysis, aka “Resistome” analysis. The concept of the microbiome is not new; however, it is only recently that it has been used to identify all resistance genes in a particular bacterium, but also the total microbiome to predict treatment failure and clinical resolution.²⁶ One downside to this type of analysis is similar to that with the other molecular based testing methods, namely that the presence of a resistance gene may not necessarily predict for phenotypic resistance. In January of 2017, van der Helm et al published a first of its kind analysis of the resistome and the clinical implications thereof.²⁶ In it they describe a cost efficient and rapid tool to determine and analyze the resistome that will inform antimicrobial treatment as the future of AST.

Summary

Since its inception, AST results have been used for appropriate antimicrobial selection and to predict successful clinical outcomes. As such, it is imperative that laboratorians perform and interpret these tests with precision and standardization. There has been a tremendous evolution of AST methods since the first days of bacterial growth visualization 70 years ago including standardization of bacterial inoculum, media type and incubation temperatures, and duration. Organizations such as CLSI, EUCAST, and the FDA have developed MIC breakpoints

in order to standardize the interpretation of susceptible, intermediate/susceptible dose dependent, or resistant. Further, while the CSLI and FDA breakpoints often differed, there has been strong interest in collaborating to standardize those as well and the first set of agreed upon breakpoints have been recently released. However, as we move into more molecular testing the question of whether we need breakpoints exists since knowing if the bacteria will or can become resistant based on the genes in the resistome may preclude the use of a particular antimicrobial anyway.

References

1. Clinical Laboratory Standards Institute, *Performance Standards for Antimicrobial Susceptibility Testing 26th ed. CLSI supplement M100S in (CLSI)*. 2016, Clinical Laboratory Standards Institute: Wayne, Pennsylvania.
2. Doern, G.V., *Antimicrobial Susceptibility Testing*. J. Clin. Micro., 2011. **49**(9 Suppl.): p. S4.
3. Clinical Laboratory Standards Institute, *Methods for Dilution Antimicrobial susceptibility Tests for Bacteria that grow Aerobically; approved standard 11th ed. CLSI Document M07-A11*. 2018, ASM Press: Wayne Pennsylvania.
4. Brennan-Krohn, T., K.P. Smith, and J.E. Kirby, *The Poisoned Well: Enhancing the Predictive Value of Antimicrobial Susceptibility Testing in the Era of Multidrug Resistance*. J Clin Microbiol, 2017. **55**(8): p. 2304-2308.
5. Fleming, A., *On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. 1929*. Bull World Health Organ, 2001. **79**(8): p. 780-90.
6. Shields, R.K., et al., *Verification of ceftazidime-avibactam and ceftolozane-tazobactam susceptibility testing methods against carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa*. J Clin Microbiol, 2017.
7. Turnidge, J.D., *Susceptibility Testing Methods: General Considerations*, in *Manual of Clinical Microbiology*, J.H. Jorgensen, et al., Editors. 2015, ASM Press: Washington, DC. p. 1246-1252.
8. Turnidge, J. and D.L. Paterson, *Setting and revising antibacterial susceptibility breakpoints*. Clin Microbiol Rev, 2007. **20**(3): p. 391-408, table of contents.

9. Jorgensen, J.H. and M.J. Ferraro, *Antimicrobial susceptibility testing: a review of general principles and contemporary practices*. Clin Infect Dis, 2009. **49**(11): p. 1749-55.
10. Labreche, M.J., C.J. Graber, and H.M. Nguyen, *Recent Updates on the Role of Pharmacokinetics-pharmacodynamics in Antimicrobial Susceptibility Testing as Applied to Clinical Practice*. Clin Infect Dis, 2015. **61**(9): p. 1446-52.
11. MacLowry, J.D., M.J. Jaqua, and S.T. Selepak, *Detailed methodology and implementation of a semiautomated serial dilution microtechnique for antimicrobial susceptibility testing*. Appl Microbiol, 1970. **20**(1): p. 46-53.
12. Doern, G.V. and S.M. Brecher, *The Clinical Predictive Value (or Lack Thereof) of the Results of In Vitro Antimicrobial Susceptibility Tests*. J. Clin Micro, 2001. **49**(9 Suppl): p. S11 - S14.
13. Clark, R.B., M.A Lewinski, M.J. Loeffelholz, and R.J. Tibbetts, *Cumitech 31A, Verification and Validation of Procedures in the Clinical Microbiology Laboratory*, S.E. Sharp, Editor. 2009, ASM Press: Washington, DC.
14. Clinical Laboratory Standards Institute, *Verification of Commercial Microbial Identification and Antimicrobial Susceptibility Testing Systems. 1st ed. CLSI M52*, (CLSI), Editor. 2015, ASM Press: Wayne, Pennsylvania.
15. Clinical Laboratory Standards Institute, *Development of in vitro susceptibility testing criteria and quality control parameters. Approved guideline, 5th ed. CLSI publication M23-A5.*, in (CLSI). 2018, ASM Press: Wayne, Pennsylvania.
16. Doern, G.V., *Interpretive criteria for the in vitro antimicrobial susceptibility tests*. Rev. Med. Microbiol., 1995. **6**: p. 126-136.

17. Forrest, A., et al., *Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients*. Antimicrob Agents Chemother, 1993. **37**(5): p. 1073-81.
18. Rex, J.H. and M.A. Pfaller, *Has antifungal susceptibility testing come of age?* Clin Infect Dis, 2002. **35**(8): p. 982-9.
19. Humphries, R.M., M.J. Ferraro, and J.A. Hindler, *Impact of 21(st) Century Cures Act on Breakpoints and Commercial Antimicrobial Susceptibility Test Systems: Progress and Pitfalls*. J Clin Microbiol, 2018.
20. United States Committee on Anti-microbial Susceptibility Testing 2017. <http://www.uscast.org/>. 2018 [cited 2018 2/20/2018].
21. Jenkins, S.G. and R.C. Jerris, *Critical Assessment of Issues Applicable to Development of Antimicrobial Susceptibility Testing Breakpoints*. J. Clin Micro, 2011. **49**(No. 9 Suppl.): p. S5-S10.
22. Craig, W.A., *Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men*. Clin Infect Dis, 1998. **26**(1): p. 1-10; quiz 11-2.
23. Abbot, A.N. and F.C. Fang, *Molecular Detection of Antibacterial Drug Resistance*, in *Manual of Clinical Microbiology*, J.H. Jorgensen, et al., Editors. 2015, ASM Press: Washington, DC.
24. Jaureguy, F., et al., *Use of the Xpert CarbaR assay for direct detection of carbapenemase genes from blood cultures and urine samples*. J Hosp Infect, 2017.
25. Ledebor, N.A. and H.L. Richard, *Molecular Detection of Resistance Determinants*. J. Clin Micro, 2011. **49**(9): p. S20-S24.
26. van der Helm, E., et al., *Rapid resistome mapping using nanopore sequencing*. Nucleic Acids Res, 2017. **45**(8): p. e61.




Figure 1.




Figure 2.

Table 1. Various indices of several families of antimicrobial agents based on the type of antimicrobial and post antimicrobial effect.

Antimicrobial Type	PAE	PK/PD Indices	Antimicrobial Class
Time Dependent	Minimal	$fT > MIC$	Beta-lactams
	Minimal	AUC:MIC	Linezolid
	Extended	AUC:MIC	Macrolides, lincosamides, Tetracycline family
Concentration Dependent	Extended	$fC_{max}:MIC$	Glycopeptides
	Minimal	AUC:MIC	Polymyxins
	Extended	AUC:MIC and/or $fC_{max}:MIC$	Aminoglycosides, quinolones, streptogramins, ketolides, Daptomycin

Adapted from Turnridge and Patterson ⁸.

Figure Legends

Figure 1. MIC distributions for a single bacterium/antimicrobial pair. As shown, the wild type population appears to be log-normally distributed at the lower MICs. CO_{WT} (aka, ECV) is the calculated wild-type cutoff value and forms the basis of the “susceptible” breakpoint. MIC’s greater than this are considered non-wildtype.

Figure 2. Comparison of zone diameters with MICs of a hypothetical antimicrobial (Reprinted from reference ⁷ with permission from the publisher). For this type of study, both the MICs and zones of inhibition are determined for a series of bacterial isolates. These values are then plotted in graphical form. The numbers within the boxes refer to the number of isolates with a particular MIC (y-axis) that matches a particular zone of inhibition (x-axis). For example, there were 12 isolates with an MIC of 0.12 ug/ml that also had a 40 mm zone of inhibition. Isolates that had MICs that were in the resistant range but were susceptible by the zone of inhibition are considered to be “very major errors”. MICs that were in the susceptible range but the zones of inhibition indicated resistant are considered to be “major errors”. When the MICs were in the intermediate ration but the zone of inhibition were either susceptible or resistant are considered to be “minor errors”.